ENDODIAG

Their core work

ENDODIAG is a French medical technology SME developing noninvasive diagnostic tests for endometriosis, a chronic gynecological condition affecting roughly 10% of women that today requires invasive laparoscopic surgery to confirm. Their core work analyzes endometrium tissue to detect disease markers without surgery, shortening the average 7-10 year diagnostic delay women currently face. They combine clinical biomarker discovery, tissue analysis, and patient stratification methods — and have expanded into the broader pain and patient-reported outcomes space through their participation in IMI-PainCare.

What they specialise in

How they've shifted over time

Their first H2020 engagement (EndoSearch, 2017) was tightly focused on a single product: a noninvasive endometriosis diagnostic, reflected in the early keywords "diagnostic", "noninvasive", "endometriosis", "women health". From 2018 onward, through IMI-PainCare, the vocabulary broadens dramatically into acute and chronic pain, bladder pain syndrome, hyperalgesia, PROMs, biomarkers, and patient stratification. The trend is clear: a product-focused diagnostic SME moving upstream into the pain-biomarker and patient-phenotyping science that underpins their core endometriosis work.

Moving from a single-product diagnostic toward broader women's health and chronic pain biomarker science — a good fit for partners working on pelvic pain, pain measurement, or biomarker-driven stratification.

How they like to work

ENDODIAG plays two distinct roles: confident coordinator of its own commercial product project (EndoSearch, SME-2) and specialist contributor inside a very large public-private pain consortium (IMI-PainCare). This combination of lead-your-own-product and embed-in-big-science consortia is typical of a focused medtech SME that knows its niche. The 40-partner / 14-country footprint comes almost entirely from IMI-PainCare, not repeat collaborations.

Connected to 40 unique partners across 14 countries — a wide European footprint driven mainly by the IMI-PainCare consortium, with France as their operating base.

What sets them apart

Few H2020 SMEs target endometriosis specifically, and even fewer have managed to coordinate a EUR 4M+ SME-2 project on a noninvasive diagnostic for the condition. ENDODIAG combines a commercial diagnostic product with scientific credibility from sitting inside one of Europe's flagship pain consortia (IMI-PainCare). Partner with them if you need clinical-grade endometrium tissue analysis, endometriosis cohort access, or a women's-health diagnostic partner fluent in both product development and biomarker science.

Highlights from their portfolio

• EndoSearch
  Coordinator of a EUR 4.23M SME-2 project building a noninvasive endometriosis diagnostic — their flagship product and the core of the company.
• IMI-PainCare
  Participation in a major Innovative Medicines Initiative public-private partnership on acute and chronic pain, placing them among 40+ partners across 14 countries.